Company news

Savara, Inc. news in 2023

Savara, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

December 20, 2023

Savara Added to the NASDAQ Biotechnology Index

December 19, 2023

Savara to Present at the Piper Sandler 35th Annual Healthcare Conference

November 20, 2023

Savara Reports Third Quarter Financial Results and Provides Business Update

November 8, 2023

Savara to Present at the Jefferies London Healthcare Conference

November 7, 2023

Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 4, 2023

Savara Reports Second Quarter Financial Results and Provides Business Update

August 9, 2023

Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

July 12, 2023

Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

June 25, 2023

Savara Added to Russell 3000® Index

June 25, 2023

Savara to Present at the Jefferies Healthcare Conference

June 1, 2023

Savara Reports First Quarter Financial Results and Provides Business Update

May 14, 2023

Savara Reports Fourth Quarter / Year-End 2022 Financial Results and Provides Business Update

March 29, 2023

Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference

March 5, 2023

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

February 27, 2023

Savara Announces New Leadership Appointments

February 13, 2023

Decks in 2023